Pharmacokinetics News and Research

RSS

The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.

“Fail Fast, But More Confidently”: Developing Organoids for Drug Development and Discovery

Richard Eglen discusses the use of organoids in drug discovery, including the screening of candidate compounds for efficacy, toxicity, and pharmacokinetics.

From Corning Life Sciences 13 Mar 2019

Successful testing of multi-organ "human-on-a-chip" could replace animals as test subjects

The replacement of animals as test subjects is one step closer to reality with the successful testing of multi-organ "human-on-a-chip" models to recapitulate the 28-day experiments typically used in animals to evaluate the systemic toxicity of drug and cosmetic compounds.

22 Feb 2019

Study quantifies hepatic and intestinal mRNA expression of Ugt isoforms in rats

In pharmaceutical companies, rats are used commonly in nonclinical studies to investigate the safety, efficacy, and pharmacokinetic profiles of drug candidates before they are entered into clinical studies. Most compounds administered via the oral route are metabolized in the liver and intestine, so the metabolism is a key determinant of pharmacokinetics.

20 Feb 2019

Keynote speakers announced for CBD Expo MIDWEST

CBD Expo Tour 2019, produced by MACE Media Group, one of the nation’s largest diversified media and information companies in the cannabis space and publisher of Terpenes and Testing Magazine, announced Celeste Miranda and Adam Dr. Adam Abodeely, MD, MBA, FACS, FASCRS will be the keynote speakers for CBD Expo MIDWEST in Indianapolis, Indiana to take place on March 15-16, 2019.

From CBD Expo Midwest 13 Feb 2019

Novel protein sensor allows researchers to observe nicotine's movements in cells

When a person takes a puff on a cigarette, nicotine floods into the brain, latching onto receptors on the surface of neurons and producing feelings of happiness. But nicotine does not simply stay on the surface of cells--the drug actually permeates into neural cells and alters them from the inside out.

8 Feb 2019

Investigational Ebola treatment found to be safe in adults

The investigational Ebola treatment mAb114 is safe, well-tolerated, and easy to administer, according to findings from an early-stage clinical trial published in The Lancet.

25 Jan 2019

Lab-Scale Clarification of Mammalian Cell Cultures Expressing Recombinant Antibodies

Tina Stoschek and Marcus Gerlach discuss maximizing mAb generation using lab-scale clarification of cell cultures expressing recombinant antibodies.

From Sartorius 23 Jan 2019

University of Nebraska to develop new drugs that prevent and counteract effects of radiation exposure

The U.S. Department of Defense has turned to the University of Nebraska to jumpstart the development of drug therapies to protect military service members from the effects of radiation exposure.

16 Jan 2019

Experts in Parkinson's research propose roadmap for drug trials targeting alpha-synuclein

A recently discovered protein, alpha-synuclein, has become one of the most attractive targets for developing new drugs with the potential to slow down or arrest the progression of Parkinson's disease

20 Dec 2018

Oral antibiotic shows promise to cure uncomplicated gonorrhea

An investigational oral antibiotic called zoliflodacin was well-tolerated and successfully cured most cases of uncomplicated gonorrhea when tested in a Phase 2 multicenter clinical trial, according to findings published today in the New England Journal of Medicine.

8 Nov 2018

Phase 2 study of ziresovir for treating hospitalized RSV infected infants achieves significant progress

Ark Biosciences, a biotech company developing proprietary therapeutics for viral infection and respiratory diseases, announced today the significant progress in its phase 2 proof-of-concept study of ziresovir in the treatment of hospitalized RSV infected infants.

1 Nov 2018

$Preclinical studies show differences in healing responses to fractured and intact stent implanted in healthy, disease models$

Preclinical studies show differences in healing responses to fractured and intact stent implanted in healthy, disease models

CBSET, a non-for-profit preclinical research institute dedicated to biomedical research, education and advancement of medical technologies, announced today that its scientists have published data and analyses ("Fracture in drug-eluting stents increases focal intimal hyperplasia in the atherosclerosed rabbit iliac artery") that "illustrate differences in the dynamic healing responses to fractured and intact stent implanted in healthy and disease rabbit models."

30 Oct 2018

Biogen and Eisai present detailed results from phase 1b study of aducanumab at CTAD meeting

Biogen and Eisai Co., Ltd. announced that Biogen presented results at the Clinical Trials on Alzheimer's Disease meeting, in Barcelona, Spain, from the recent 36- and 48-month analyses of the ongoing long-term extension of the Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment due to Alzheimer's disease and mild AD.

29 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

Pfizer Inc. today announced detailed overall survival data from the PALOMA-3 trial, which evaluated IBRANCE (palbociclib) in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer whose disease progressed on or after prior endocrine therapy.

22 Oct 2018

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Takeda Pharmaceutical Company Limited today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients.

22 Oct 2018

Using Galleria mellonella to assess acute toxicity of chemicals

TruLarv is considered a non-animal technology in the context of UK animal use regulations where procedures on this species are not regulated.

17 Oct 2018

FDA approves HEMLIBRA for treatment of hemophilia A

Chugai Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved HEMLIBRA (US generic name: emicizumab-kxwh), a treatment for hemophilia A created by Chugai, for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A without factor VIII inhibitors, administered once weekly, every two weeks, or every four weeks.

5 Oct 2018

New PET imaging radiotracer could help understand the aging brain

A new PET imaging radiotracer could help researchers understand neurodegenerative disease and the aging brain. The study is featured in the October issue of The Journal of Nuclear Medicine.

4 Oct 2018

New ReFRAME drug repurposing collection offers hope for treating major diseases

Each year, millions of people worldwide suffer from potentially fatal infectious diseases that often leave survivors facing a lifetime of related health problems. But what if drugs against such diseases already existed but nobody knew it?

4 Oct 2018

Pharmacokinetics News and Research

Further Reading

“Fail Fast, But More Confidently”: Developing Organoids for Drug Development and Discovery

Successful testing of multi-organ "human-on-a-chip" could replace animals as test subjects

Study quantifies hepatic and intestinal mRNA expression of Ugt isoforms in rats

Keynote speakers announced for CBD Expo MIDWEST

Novel protein sensor allows researchers to observe nicotine's movements in cells

Investigational Ebola treatment found to be safe in adults

Lab-Scale Clarification of Mammalian Cell Cultures Expressing Recombinant Antibodies

University of Nebraska to develop new drugs that prevent and counteract effects of radiation exposure

Experts in Parkinson's research propose roadmap for drug trials targeting alpha-synuclein

Oral antibiotic shows promise to cure uncomplicated gonorrhea

Phase 2 study of ziresovir for treating hospitalized RSV infected infants achieves significant progress

Preclinical studies show differences in healing responses to fractured and intact stent implanted in healthy, disease models

Biogen and Eisai present detailed results from phase 1b study of aducanumab at CTAD meeting

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Using Galleria mellonella to assess acute toxicity of chemicals

FDA approves HEMLIBRA for treatment of hemophilia A

New PET imaging radiotracer could help understand the aging brain

New ReFRAME drug repurposing collection offers hope for treating major diseases

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News